Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases
ConditionAutoimmune Diseases
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAnhui Provincial Hospital
About this trial
This is an open label, single-site, dose-escalation study in up to 18 participants with treatment of Refractory Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with an Anti- CD19/BCMA CAR gene vector injection
Eligibility criteria
Qualifiers
( 1) At the time of signing the informed consent form, be at least 18 years of age, both male and female.
Disqualifiers
(1) Clinically significant central nervous system diseases or pathological changes not caused by the disease itself before screening, including but not limited to: stroke, stroke, aneurysm, epilepsy, convulsions, aphasia, severe head injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome or mental disorder.
Trial design
Treatments tested in this trial
- Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis
Treatment groups
18 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov